Connect with us

Hi, what are you looking for?

Monday, Feb 6, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.

Psychedelics

Awakn set to research ketamine for alcohol use disorder

The trial will be held at 7 NHS sites in the U.K. with the NIHR funding 66% of the cost

Awakn set to research ketamine on alcohol use disorder
Photo by Pixabay via Pexels

Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) has received a $2.5 million grant from health authorities in the United Kingdom to research how ketamine can help people suffering from alcohol use disorder (AUD).

On Tuesday, the biotechnology company announced that its upcoming psychedelic trial combatting the harmful effects of drinking would be held at seven National Health Service (NHS) sites throughout the U.K.

The National Institute for Health and Care Research (NIHR), a government organization there, will be providing the grant and Awakn will cover the remaining $1.25 million in required funding for the $3.75 million endeavour.

Celia Morgan, Head of Ketamine-Assisted Therapy for Awakn says that alcohol has a tremendous negative impact on the community and that deaths related to it have only increased since the pandemic.

She also says new treatments to combat AUD are urgently needed and that she is hoping for positive results in this trial so that ketamine therapy will start being used in NHS settings.

Read more: Health Canada provides guidance for clinical trials on psychedelics

Read more: Field Trip offers free psychedelic-assisted therapy for laid off tech workers

The trial will be conducted by the University of Exeter (UoE) and led by Morgan. It will recruit 280 people suffering from severe AUD.

The new study will build on positive results yielded by the Phase II portion of the trials in January which resulted in participants having an 86 per cent rate of abstinence from alcohol six months post-treatment.

The company, the NHS and the UoE will be collaborating with the U.K. Department of Health and Social Care and other stakeholders during the course of the study to help promote uptake of the treatment within the NHS post-trial, depending on how successful it is.

Awakn conducts Stage III ketamine trial to treat severe AUD

Awakn’s Head of Ketamine-Assisted Therapy, Celia Morgan & Chief Research Officer, David Nutt. Photo via Awakn Life Sciences

Awakn anticipates that the trial will be the largest ketamine-assisted therapy study ever conducted and the only government-funded Phase III psychedelics trial to date.

“More than two million U.K. adults have serious alcohol problems, yet only one in five of those get treatment. Unfortunately, three out of four people who quit alcohol will be back drinking heavily after a year. Alcohol-related harm is estimated to cost the NHS around £3.5 billion each year, and wider U.K. society around £40 billion,” said Morgan.

 

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Rowan Dunne on Twitter

rowan@mugglehead.com

 

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Psychedelics

The AUD$5M study will involve about 160 participants and aims to help combat treatment-resistant depression

Psychedelics

The program's creation was inspired by new regulations for psychedelic-assisted therapy in Alberta

Psychedelics

The company believes this to be the largest shipment of MDMA the government department has ever approved

Psychedelics

The development marks a 'watershed moment for psilocybin research' says the company's CEO